Blockchain Registration Transaction Record

Lantern Pharma Closes $4M Registered Direct Offering

Lantern Pharma closes $4M registered direct offering, issuing 3.67M shares at $1.09 plus warrants. Proceeds to fund AI-driven oncology pipeline and operations.

This financing provides Lantern Pharma with additional capital to advance its AI-driven oncology pipeline, including LP-184, LP-300, and LP-284, and to support its subsidiaries Starlight Therapeutics and Open-Medicine AI. As a clinical-stage company, access to funding is critical for progressing biomarker-driven clinical trials and potentially bringing new precision cancer therapies to patients. The offering, though modest, signals continued investor interest in AI-native drug development and could enable Lantern to achieve key milestones. For investors, the dilution from the new shares and warrants is a consideration, but the funds strengthen the balance sheet and support the company’s mission to transform oncology drug development. This news matters because it highlights the ongoing convergence of artificial intelligence and biopharma, a trend that could lead to faster, more effective cancer treatments.